New Rx-NAPT Tool Can Help Predict Risk of Noncompliance Among Fibromyalgia Patients

New Rx-NAPT Tool Can Help Predict Risk of Noncompliance Among Fibromyalgia Patients
The newly developed Prescription Medication Non-Adherence Prediction Tool, or Rx-NAPT, may help clinicians identify patients with fibromyalgia who are more likely not to comply with the prescribed treatment. This tool can improve communication between patients and healthcare providers, reducing the social, clinical, and economic burden of correcting noncompliance in patients with fibromyalgia. Rx-NAPT was described in the retrospective study “Risk of medication non‐adherence among Medicaid enrollees with fibromyalgia: Development of a validated risk prediction tool” that appeared in the journal Pain Practice. Fibromyalgia is associated with a high economic burden to patients, but also to society. Studies have shown that direct healthcare costs are three times higher for fibromyalgia patients than for those without the disease. Indirect costs such as pain and loss of productivity are more than two times higher in these patients. According to data from 2007, about 34 percent of fibromyalgia patients in the United States spend between $100 and $1,000 per month beyond their insurance to see a healthcare professional. This is an important contributing factor in high noncompliance rates among these patients. “Unfortunately, payers frequently pass the subsequent financial pressures over to patients through higher copayment mechanisms, a process which plays a further role in non-adherence,” researchers stated. To improve patient outcomes and reduce the burden associat
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *